Fusion Antibodies Plc

Fusion Antibodies (FAB)

Company name:Fusion Antibodies Plc
EPIC:FABTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BDQZGK16
Market Segment:ASQ1Share Type:DE
WWW Address:http://www.fusionantibodies.com/Description:ORD 4P
 Price Price Change [%] Bid Offer Open High Low Volume
 127.50 images.advfn.com/imagesnew/2/gb/up 7.5 [6.25] 120.00 135.00 120.00 127.50 120.00 39,617
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 32.43 25.44 0.01 -3.20 - - - 250.00 - 54.50

Fusion Antibodies Key Figures

(at previous day's close)
Market Cap.32.43m
Shares In Issue25.44m
Prev. Close120.00
PE Ratio- 
Dividend Yield-%
EPS - basic-3.20p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-0.63p
Return On Equity (ROE)-14.48%
Operating Margin-27.55%
PEG Factor- 
EPS Growth Rate43.86%
Dividends PS Growth Rate-%
Net Debt-0.31m
Gross Gearing20.33%
Quick Assets4.23m
Net Working Capital3.58m
Intangibles / Fixed Assets0.27%
Turnover PS15.31p
Pre-Tax Profit PS-4.22p
Retained Profit PS-2.74p
Cash PS6.04p
Net Cash PS2.15p
Net Tangible Asset Value PS *18.90p
Net Asset Value PS18.92p
Spread15.00 (11.11%) 

Fusion Antibodies Balance Sheet


Share Price Performance

Sample Period HighLow
1 week134.50107.00
4 weeks150.00105.50
12 weeks155.0090.00
1 year250.0054.50

Share Price Chart (5 years)

Fusion Antibodies Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week115.0012.5010.87107.000.03122.67
4 weeks126.501.000.79105.500.04130.76
12 weeks140.00-12.50-8.9390.000.05122.88
26 weeks90.0037.5041.6777.500.07154.19
1 year88.5039.0044.0754.500.06138.64
3 years155.00-27.50-17.7424.500.03130.06
5 years83.5044.0052.6924.500.03132.08

Fusion Antibodies Key Management Ratios

Fusion Antibodies Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 5.28 
Tobin's Q Ratio (excl. intangibles)5.29 
Dividend Yield-%
Market-to-Book Ratio6.74 
Price-to-Pre-Tax Profit PS-30.23 
Price-to-Retained Profit PS-46.53 
Price-to-Cash Flow PS-202.70 
Price-to-Sales PS8.33 
Price-to-Net Tangible Asset Value PS6.75 
Price-to-Cash PS21.10 
Net Working Capital PS14.06 
Price Pct to Working Capital PS9.07%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Fusion Antibodies Financial Ratios

(Leverage Ratios)
Debt Ratio4.73%
Debt-to-Equity Ratio0.05 
Debt-to-Equity Ratio (excl. Intgbl)0.05 
Debt-to-Equity Market Value0.01 
Net Gearing-5.12%
Net Gearing (excl. Intangibles)-5.12%
Gross Gearing20.33%
Gross Gearing (excl. Intangibles)20.34%
Gearing Under 1 Year16.37%
Gearing Under 1 Year (excl. Intgbl)16.39%
(Liquidity Ratios)
Net Working Capital to Total Assets59.22%
Current Ratio4.62 
Quick Ratio (Acid Test)4.27 
Liquidity Ratio1.55 
Cash & Equiv/Current Assets33.66%
(Solvency Ratios)
Enterprise Value31.13m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.04 
Total Debt/Sales0.32 
Total Debt/Pre-Tax Profit-1.14 
Total Debt1.23m
Total Debt/Net Current Assets0.34%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-9.38%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs1 
Beta (60-Mnth)Beta (36-Mnth)

Fusion Antibodies Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-21.24%
Return On Assets (ROA)-11.35%
Net Profit Margin-17.89%
Assets Turnover0.63 
Return On Equity (ROE)-14.48%
Return On Investment (ROI)-13.28%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-17.89%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.77 
Fixed Assets Turnover2.54 
Current Assets Turnover0.85 
Net Working Capital Turnover 
Inventory Turnover13.37 
(Other Operating Ratios)
Total Assets-to-Sales1.58 
Debt Collection Period239.45Days

Fusion Antibodies Dividends

Sorry No Data Available

Fusion Antibodies Fundamentals

 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)
pre tax profit-0.71-26.44%-1.50-68.74%-1.07-27.55%m
attributable profit-0.70-26.01%-1.26-57.95%-0.70-17.89%m
retained profit-0.70-26.01%-1.26-57.95%-0.70-17.89%m
eps - basic (p)-4.30 -5.70 -3.20 
eps - diluted (p)-4.30 -5.70 -3.20 
dividends per share- - - 

Fusion Antibodies Balance Sheet

 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)
 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)
fixed assets fixed assets0.557.58%1.5925.44%1.4724.34%m
intangibles intangibles--%0.010.10%0.000.07%m
fixed investments fixed investments--%--%--%m
current assets - other current assets - other--%--%--%m
stocks stocks0.081.13%0.243.89%0.345.63%m
debtors debtors2.0928.98%2.4238.79%2.6944.52%m
cash & securities cash & securities4.4962.30%1.9831.79%1.5425.45%m
creditors - short creditors - short0.577.91%0.8012.75%0.9916.37%m
creditors - long creditors - long0.060.88%0.091.48%0.243.96%m
creditors - other creditors - other--%--%--%m
subordinated loans subordinated loans--%--%--%m
insurance funds insurance funds--%--%--%m
ord cap, reserves ord cap, reserves6.5891.21%5.3585.77%4.8179.67%m
prefs, minorities prefs, minorities--%--%--%m
NAV Basic- - - 
NAV Diluted- - - 

Fusion Antibodies Cash Flow Statement

31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)
Operating CF0.08-1.10-0.16m
Pre-Financing CF-0.37-2.48-0.26m
Retained CF4.21-2.51-0.45m

Fusion Antibodies Brokers

Fairfax I.S. PLCMarket Maker(MMF)Broker/DealerFFAXFRFXGB21001
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210122 16:42:58